Beyond Weight Loss: Examining Promise and Risks of GLP-1 Drugs
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have transformed the management of obesity and Type 2 diabetes, yet high costs, high drop-off rates, and youth developmental risks present significant challenges. Panel experts explore the psychological mechanisms, historical stress factors, potential pediatric concerns, and real-world patient experiences surrounding these blockbuster drugs. Ultimately, the briefing emphasizes that long-term metabolic health requires equitable access, intensive lifestyle support, and compassionate, destigmatized medical care.
1. The Unprecedented Surge of GLP-1 Medications
GLP-1 (glucagon-like peptide-1) receptor agonists were originally created to treat Type 2 diabetes, but they have quickly become a cultural and medical phenomenon in the United States. Medications such as semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) mimic natural gut hormones to regulate appetite and dramatically quiet down what patients refer to as "food noise." Today, GLP-1s represent a staggering $130 billion industry in the US, accounting for roughly 14% of all prescription drug spending. 📈
This surge meets a pressing public health need: over 40% of American adults live with obesity, and nearly 1 in 5 children and adolescents are affected. In response, the FDA has approved certain GLP-1 medications for adolescents aged 12 and older. However, this rapid adoption raises crucial questions:
- How long should patients stay on these medications?
- What happens when treatment stops?
- Are there unintended impacts on developing adolescent bodies or aging muscles and bones?
- Who actually has affordable access to these expensive treatments?
Although these drugs are designed for lifelong chronic disease management, real-world data reveals that over half of all patients stop taking GLP-1s within a single year.
2. Psychological and Behavioral Impacts of GLP-1s
Dr. Jena Shaw Tronieri, a senior research investigator at the University of Pennsylvania's Perelman School of Medicine, opened the panel by explaining why weight loss through traditional diet and exercise alone is so mentally and physically exhausting.
Human biology evolved over thousands of years to guard against starvation by storing extra energy as fat. Therefore, actively choosing to eat less requires constant, conscious effort against your body's natural biology. GLP-1 medications help lower this daily effort by altering signals related to hunger and reward.
"You have to sort of actively choose to eat less than is usual for you and you have to do that consistently, day after day, regardless of whatever other demands you might face. And really, your body's biology is not designed to help you with weight loss. In fact, it's much better equipped to help prevent against starvation."
Clinically, patients describe a total absence of constant food preoccupation.
"I've had some patients say to me that they didn't even realize how constantly they were thinking about food throughout the day until they started the GLP-1 medication and that food noise was suddenly gone."
Dr. Tronieri shared the findings of her recent 60-week study comparing semaglutide with a placebo alongside monthly lifestyle counseling:
- Hunger & Food Noise: By week 20 (the active weight loss phase), patients on semaglutide experienced dramatic reductions in hunger and food noise. Surprisingly, by weeks 40 and 60, self-reported hunger levels in the semaglutide group matched those of the placebo group.
- Calorie Intake: Despite feeling similar hunger levels later in the study, participants taking semaglutide continued to eat 240 to 290 fewer calories during lab lunch tests compared to the placebo group all the way through week 60.
- Overall Weight Loss: The semaglutide group achieved an average loss of about 34 pounds (15.5 kg) by week 60, whereas the placebo group peaked at around 11.5 pounds (5 kg) before regaining weight.
These findings show that semaglutide helps keep calorie intake down even as weight loss reaches a plateau and transitions into long-term maintenance.
When patients stop taking GLP-1s, research shows that about two-thirds of the lost weight is regained within the first year.
"When we see patients that do discontinue, about two-thirds of the weight that they had lost is regained in the first year after they stop taking the GLP-1 medication."
Dr. Tronieri emphasized that weight regain is not a personal failure or a lack of willpower. Just as blood pressure rises when hypertension medication is discontinued, body weight returns when biological weight-management support is removed. 🧠💡
3. Historical Stress, Biological Realities, and Access Disparities
Dr. Fatima Cody Stanford, an Associate Professor of Medicine and Pediatrics at Harvard Medical School, shifted the focus to the root causes of obesity and systemic inequities in healthcare access.
Obesity is a complex disease of energy regulation, driven by genetics, brain chemistry, hormones, sleep, stress, and environmental factors—not a simple character flaw.
"Obesity is a disease of energy regulation. It is not a failure of willpower."
When examining obesity among Black women in America—who currently experience the highest prevalence of obesity across demographic groups—Dr. Stanford stressed that the timeline does not begin with modern fast food or suburban lifestyles. Instead, it traces back over a century to the allostatic load (the cumulative physical wear and tear on the body caused by chronic stress) originating during slavery and carried forward through epigenetics and generational economic exclusion.
"So, when we talk about disparities in obesity prevalence about Black women today... we have to stop treating it as if it was a recent lifestyle trend and start treating it as a predictable outcome of nearly two centuries of accumulated stress physiology, economic exclusion, and a healthcare system that was not designed with Black women's health in mind."
To address coverage gaps, CMS launched the Medicare GLP-1 Bridge Program as of July 1, 2026. Qualifying beneficiaries (typically those with a BMI of 35+, or 30+ with related health conditions) can access select GLP-1 treatments like Wegovy for a co-pay of $50 a month, down from list prices ranging between $900 and $1,300 a month.
However, Dr. Stanford warned that administrative hurdles like prior authorization—which requires a physician to submit complex paperwork—can prevent vulnerable communities with limited primary care access from receiving care.
"Prior authorization requires a consistent relationship with a physician who knows how to code and submit that request, and time to navigate a burdensome administrative process. Communities with less consistent access to primary care... are the ones most likely to fall through the cracks of a program that on paper is supposed to help them."
Dr. Stanford also noted clear contraindications where GLP-1 drugs should not be used:
- Multiple Endocrine Neoplasia type 2 (MEN 2)
- Medullary thyroid cancer
- A severe history of recurrent pancreatitis 🚫
4. Caution and Concerns Surrounding Youth Prescriptions
Dr. Dan Cooper, Distinguished Professor Emeritus of Pediatrics at UC Irvine, expressed serious concerns about the rapid growth of GLP-1 prescriptions for adolescents and younger children.
Human adolescence is a unique developmental window characterized by long periods of rapid bone mineralization, muscle growth, and neural development. Peak bone mass established between ages 10 and 25 determines skeletal health for a lifetime; disrupting this window could increase the risk of osteoporosis decades later.
"Adolescence in childhood, and particularly in humans, is completely unique. No other mammal experiences adolescence the way human beings do... Bone is developing rapidly. Muscle is developing rapidly... when this process is interfered with, the long-term consequences can be quite severe."
Because GLP-1 receptors are located predominantly in the brain, GLP-1 drugs act as anti-hedonic agents—meaning they reduce the biological brain rewards associated with eating. Giving these brain-altering medications to developing adolescents over long periods presents significant unknown risks.
"This is an anti-hedonic drug... So now we've got a drug that we're going to give to adolescents for who knows how long that is flooding a receptor in a developing brain. I don't know what the long-term consequences are."
Dr. Cooper emphasized that weight loss causes the body to break down both fat and lean muscle tissue. Without structured physical activity, growing children risk losing vital muscle mass and bone density.
He urged healthcare systems to invest heavily in physical literacy—teaching kids the lifelong value and enjoyment of movement—and intensive lifestyle interventions alongside medical therapies.
"Until we know more about the physiology of growth and development on children and adolescents who are taking these medications, at the very least, we should be investing in really, really good and effective lifestyle interventions to accompany the use of these medications in those kids..." 🏋️♂️🦴
5. A Firsthand Account of the GLP-1 Patient Journey
Jasmyne Cannick, a 48-year-old Gen X journalist and political strategist from Los Angeles, shared her personal journey navigating GLP-1 medications over the past several years.
She began taking Ozempic four to five years ago after learning she was on the verge of a Type 2 diabetes diagnosis. Weighing approximately 250 pounds at 5'6", her primary motivation was avoiding severe metabolic complications like those suffered by older family members.
"My introduction to GLP-1s was through scientific... healthcare provider... I did not want to have bariatric surgery, but I also didn't want to end up like some of my relatives with amputations and these, you know, horrible health conditions in their older years."
Her experience highlights several common real-world challenges:
- Side Effect Oversight: Early in her treatment, lack of guidance around fluid and fiber intake led to severe constipation and an emergency room visit.
- Financial Volatility: While she initially paid a modest $25 monthly copay, insurance shifts caused her out-of-pocket costs to surge to nearly $800 a month for Ozempic.
- Plateaus and Drug Switching: After weight loss plateaued on Ozempic, her physician transitioned her to Zepbound (tirzepatide), which helped her safely reach her target weight of 185 pounds.
Jasmyne actively pairs her treatment with regular physical activity, playing tennis three times a week, and working on long-term nutritional changes. While she wants to maintain her health, she has no desire to lose excessive body weight or sacrifice her natural body shape.
"I went from paying $25 to paying almost $800 a month to be on Ozempic, and I was really upset about that... There's a story behind everyone who takes these medicines. It's not just because we all want to be skinny." 🎾✨
6. Panelists' Key Takeaways and Final Messages
To wrap up the briefing, each speaker offered a concise takeaway for the public and media:
- Dr. Jena Shaw Tronieri: Reminded patients that weight loss naturally levels off into a sustainable "new normal," reassuring them that staying on treatment maintains weight stability without causing them to continuously lose weight indefinitely.
- Dr. Dan Cooper: Reiterated that pediatric care must prioritize long-term, lifelong health rather than rapid weight loss alone, ensuring every young patient receives comprehensive lifestyle support.
- Jasmyne Cannick: Encouraged open, judgment-free conversations around body image, healthcare access, and personal well-being.
- Dr. Fatima Cody Stanford: Called for an immediate shift in how society speaks about and treats individuals living with high body weight.
"We need to treat patients with obesity with kindness, dignity, and respect. Let's get rid of the word 'obese.' Let's get rid of the word 'morbid' as it relates to obesity. And let's not assume that everyone's just eating bad and not exercising... I will continue to treat this patient population with the kindness, dignity, and respect that they deserve."
Conclusion
GLP-1 medications represent a powerful breakthrough in modern medicine, offering meaningful metabolic benefits for millions of adults and adolescents. However, as the panel highlighted, these medications are not a quick, standalone fix. Sustainable public health outcomes require long-term adherence, equitable insurance coverage, careful monitoring of adolescent development, and robust lifestyle education. Above all, effective care requires treating obesity as a complex chronic disease with empathy, dignity, and equal access for all communities.
Need a summary like this?
Get instant summaries with Harvest